Literature DB >> 9227161

Dyslipidemia and rheumatoid arthritis.

R D Situnayake1, G Kitas.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1997        PMID： 9227161      PMCID： PMC1752397          DOI： 10.1136/ard.56.6.341

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN： 0003-4967            Impact factor:   19.103


× No keyword cloud information.
  30 in total

1.  Effect of disease modifying agents on the lipid profiles of patients with rheumatoid arthritis.

Authors:  R Munro; E Morrison; A G McDonald; J A Hunter; R Madhok; H A Capell
Journal:  Ann Rheum Dis       Date:  1997-06       Impact factor: 19.103

2.  Lipid abnormalities in renal transplant recipients treated with cyclosporine.

Authors:  A Vathsala; R B Weinberg; L Schoenberg; J Grevel; J Dunn; R A Goldstein; C T Van Buren; R M Lewis; B D Kahan
Journal:  Transplant Proc       Date:  1989-08       Impact factor: 1.066

Review 3.  Mortality in rheumatoid arthritis.

Authors:  R A Myllykangas-Luosujärvi; K Aho; H A Isomäki
Journal:  Semin Arthritis Rheum       Date:  1995-12       Impact factor: 5.532

Review 4.  The use of antimalarials in combination with other disease modifying agents in RA--the British experience.

Authors:  M R Duncan; H A Capell
Journal:  Lupus       Date:  1996-06       Impact factor: 2.911

5.  Cardiovascular mortality in rheumatoid arthritis: how harmful are corticosteroids?

Authors:  J P Raynauld
Journal:  J Rheumatol       Date:  1997-03       Impact factor: 4.666

6.  Serum lipoprotein in active rheumatoid arthritis and other chronic inflammatory arthritides. II. Effects of anti-inflammatory and disease-modifying drug treatment.

Authors:  K L Svenson; H Lithell; R Hällgren; B Vessby
Journal:  Arch Intern Med       Date:  1987-11

7.  Cardiovascular morbidity and mortality in patients with seropositive rheumatoid arthritis in Northern Sweden.

Authors:  S Wallberg-Jonsson; M L Ohman; S R Dahlqvist
Journal:  J Rheumatol       Date:  1997-03       Impact factor: 4.666

8.  Glutathione reductase activity, riboflavin status, and disease activity in rheumatoid arthritis.

Authors:  D M Mulherin; D I Thurnham; R D Situnayake
Journal:  Ann Rheum Dis       Date:  1996-11       Impact factor: 19.103

9.  Serum lipoprotein in active rheumatoid arthritis and other chronic inflammatory arthritides. I. Relativity to inflammatory activity.

Authors:  K L Svenson; H Lithell; R Hällgren; I Selinus; B Vessby
Journal:  Arch Intern Med       Date:  1987-11

10.  Serum total, HDL, LDL cholesterol, and triglyceride levels in patients with rheumatoid arthritis.

Authors:  J Lakatos; A Hárságyi
Journal:  Clin Biochem       Date:  1988-04       Impact factor: 3.281
View more
  21 in total

Review 1.  [Rheumatoid arthritis and cardiovascular complications].

Authors:  W Seidel; M Hecker; U Wagner; H Häntzschel
Journal:  Z Rheumatol       Date:  2006-10       Impact factor: 1.372

2.  Positive effect of hydroxychloroquine on lipid profiles of patients with rheumatoid arthritis: A Veterans Affair cohort.

Authors:  Myriam Guevara; Bernard Ng
Journal:  Eur J Rheumatol       Date:  2020-11-05

Review 3.  The swollen joint, the thickened artery, and the smoking gun: tobacco exposure, citrullination and rheumatoid arthritis.

Authors:  Natalí Serra-Bonett; Martín A Rodríguez
Journal:  Rheumatol Int       Date:  2010-12-07       Impact factor: 2.631

4.  Effect of Erythrina variegata seed extract on hyperlipidemia elicited by high-fat diet in wistar rats.

Authors:  G Balamurugan; A Shantha
Journal:  J Pharm Bioallied Sci       Date:  2010-10

Review 5.  Novel mechanisms of action of the biologicals in rheumatic diseases.

Authors:  Cecilia Beatrice Chighizola; Ennio Giulio Favalli; Pier Luigi Meroni
Journal:  Clin Rev Allergy Immunol       Date:  2014-08       Impact factor: 8.667

6.  Increased levels of antibodies to cytokeratin 18 in patients with rheumatoid arthritis and ischaemic heart disease.

Authors:  D L Mattey; P T Dawes; N B Nixon; L Goh; M J Banks; G D Kitas
Journal:  Ann Rheum Dis       Date:  2004-04       Impact factor: 19.103

7.  Strategies for implementation of guideline recommended cardiovascular risk management for patients with rheumatoid arthritis: results from a questionnaire survey of expert rheumatology centers.

Authors:  Julia M Weijers; Anne G Semb; Silvia Rollefstad; George D Kitas; Piet L C M van Riel
Journal:  Rheumatol Int       Date:  2020-02-22       Impact factor: 2.631

8.  Serum oxidized low-density lipoproteins in rheumatoid arthritis.

Authors:  Seong-Ho Kim; Chang-Keun Lee; Eun Young Lee; So Yeon Park; You Sook Cho; Bin Yoo; Hee-Bom Moon
Journal:  Rheumatol Int       Date:  2003-11-20       Impact factor: 2.631

9.  Lack of association between glucocorticoid use and presence of the metabolic syndrome in patients with rheumatoid arthritis: a cross-sectional study.

Authors:  Tracey E Toms; Vasileios F Panoulas; Karen M J Douglas; Helen R Griffiths; George D Kitas
Journal:  Arthritis Res Ther       Date:  2008-12-17       Impact factor: 5.156

10.  Comorbidity profile among patients with rheumatoid arthritis and the impact on prescriptions trend.

Authors:  J Al-Bishri; Sm Attar; Nawal Bassuni; Yasser Al-Nofaiey; Hamed Qutbuddeen; Salma Al-Harthi; Sarah Subahi
Journal:  Clin Med Insights Arthritis Musculoskelet Disord       Date:  2013-04-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.